HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...

Dr. Prince will provide an overview of Herpes Simplex Virus (HSV), including the distinctions between HSV-1 and HSV-2, their anatomical sites of infection, and the mechanisms underlying viral ...

Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical ...

Eurocine Vaccines AB has reported findings from preclinical studies evaluating its mRNA and protein technology platforms for its therapeutic herpes simplex virus type 2 (HSV-2) vaccine candidates.

– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in ...

The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...

WOBURN, Mass. and OXFORD, England, Dec. 14, 2021 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today ...

There's more unwelcome news for sufferers of genital herpes. Less than a year after Genocea's experimental herpes vaccine went down in flames, Vical's VCL-HB01 met the same fate: no efficacy in Phase ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...